1. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Issue 1 (January 2019) Authors: Jackson, Graham H; Davies, Faith E; Pawlyn, Charlotte; Cairns, David A; Striha, Alina; Collett, Corinne; Hockaday, Anna; Jones, John R; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D; Karunanithi, Kamaraj; Lindsay, Jindriska; Jenner, Matthew W; Cook, Gordon; Russell, Nigel H; Kaiser, Martin F; D... Journal: Lancet oncology Issue: Volume 20:Issue 1(2019) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial. (12th July 2020) Authors: Jackson, Graham H.; Pawlyn, Charlotte; Cairns, David A.; Striha, Alina; Collett, Corinne; Waterhouse, Anna; Jones, John R.; Wilson, Jamie; Taylor, Craig; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D.; Karunanithi, Kamaraj; Lindsay, Jindriska; Jenner, Matthew W.; Cook, Gordon; Russell, Nigel H.... Journal: British journal of haematology Issue: Volume 192:Number 5(2021) Page Start: 853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. (22nd September 2021) Authors: Richardson, Paul G.; Schjesvold, Fredrik; Weisel, Katja; Moreau, Philippe; Anderson, Larry D.; White, Darrell; Rodriguez‐Otero, Paula; Sonneveld, Pieter; Engelhardt, Monika; Jenner, Matthew; Corso, Alessandro; Dürig, Jan; Pavic, Michel; Salomo, Morten; Beksac, Meral; Oriol, Albert; Lindsay, Jindr... Journal: European journal of haematology Issue: Volume 108:Number 1(2022) Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Issue 6 (June 2019) Authors: Richardson, Paul G; Oriol, Albert; Beksac, Meral; Liberati, Anna Marina; Galli, Monica; Schjesvold, Fredrik; Lindsay, Jindriska; Weisel, Katja; White, Darrell; Facon, Thierry; San Miguel, Jesus; Sunami, Kazutaka; O'Gorman, Peter; Sonneveld, Pieter; Robak, Pawel; Semochkin, Sergey; Schey, Steve; Y... Journal: Lancet oncology Issue: Volume 20:Issue 6(2019) Page Start: 781 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open‐label, randomised, phase III trial. (21st December 2022) Authors: Jenner, Matthew W.; Pawlyn, Charlotte; Davies, Faith E.; Menzies, Tom; Hockaday, Anna; Olivier, Catherine; Jones, John R.; Karunanithi, Kamaraj; Lindsay, Jindriska; Kishore, Bhuvan; Cook, Gordon; Drayson, Mark T.; Kaiser, Martin F.; Owen, Roger G.; Gregory, Walter; Cairns, David A.; Morgan, Garet... Journal: British journal of haematology Issue: Volume 201:Number 2(2023) Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗